navoximod

IDO1 inhibitor

Also Known As:

5H-Imidazo(5,1-a)isoindole-5-ethanol, 6-fluoro-alpha-(trans-4-hydroxycyclohexyl)-, (alphaR,5S)-; GDC-0919; trans-4-((1R)-2-((5S)-6-Fluoro-5H-imidazo(5,1-a)isoindol-5-yl)-1-hydroxyethyl)cyclohexanol

Networked: 10 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - navoximod: 10
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - navoximod: 10

Experts

1.	Pirzkall, Andrea: 3 articles (01/2019 - 01/2018)
2.	Liang, Xiaorong: 2 articles (01/2019 - 01/2018)
3.	Mahrus, Sami: 2 articles (01/2019 - 01/2018)
4.	Morley, Roland: 2 articles (01/2019 - 01/2019)
5.	Morrissey, Kari M: 2 articles (01/2019 - 01/2018)
6.	Royer-Joo, Stephanie: 2 articles (01/2019 - 01/2018)
7.	Salphati, Laurent: 2 articles (01/2019 - 01/2018)
8.	Suchomel, Julia: 2 articles (01/2019 - 01/2019)
9.	Adam, Julien: 1 article (01/2020)
10.	Bessede, Alban: 1 article (01/2020)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2018 - "This open-label Phase Ia study assessed safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of navoximod in patients with recurrent/advanced solid tumors, administered as 50-800 mg BID on a 21/28 day and at 600 mg on a 28/28 day schedule. " 01/01/2023 - "To solve the above problems, we identified that Indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor Navoximod promoted herpes simplex virus type 1 (HSV-1) replication and HSV-1-mediated oncolysis in tumor cells, making it a promising combination modality with HSV-1-based virotherapy. " 01/01/2019 - "Navoximod (GDC-0919, NLG-919) is a small molecule inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1), developed to treat the acquired immune tolerance associated with cancer. " 01/01/2018 - "The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919) is active as a combination therapy in multiple tumor models. " 01/01/2018 - "Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors."
2.	Glioblastoma (Glioblastoma Multiforme) 01/01/2018 - "Although GDC-0919 as a single agent did not demonstrate antitumor activity, it had a strong potential for enhancing RT response in glioblastoma, which was further augmented with a hypofractionated regimen. " 01/01/2018 - "Here, we studied the intermediary metabolism of tryptophan metabolism in glioblastoma and evaluated the activity of the IDO1 inhibitor GDC-0919, both alone and in combination with radiation (RT).Experimental Design: LC/GC-MS and expression profiling was performed for metabolomic and genomic analyses of patient-derived glioma. " 12/15/2015 - "Inhibitors currently in clinical trials, INCB024360, GDC-0919, indoximod, and an IDO1 peptide-based vaccine, are being evaluated for their efficacy against a wide range of cancers including melanoma, glioblastoma, non-small cell lung, pancreatic, and/or breast cancer, as well as metastatic disease. "
3.	Melanoma (Melanoma, Malignant) 12/15/2015 - "Inhibitors currently in clinical trials, INCB024360, GDC-0919, indoximod, and an IDO1 peptide-based vaccine, are being evaluated for their efficacy against a wide range of cancers including melanoma, glioblastoma, non-small cell lung, pancreatic, and/or breast cancer, as well as metastatic disease. "
4.	Breast Neoplasms (Breast Cancer) 12/15/2015 - "Inhibitors currently in clinical trials, INCB024360, GDC-0919, indoximod, and an IDO1 peptide-based vaccine, are being evaluated for their efficacy against a wide range of cancers including melanoma, glioblastoma, non-small cell lung, pancreatic, and/or breast cancer, as well as metastatic disease. "
5.	Chromosomal Instability (Chromosome Stability) 12/15/2023 - "The in vitro biological assays on IDO1+ CAFs co-cultured OSCC cancer cells supported that combined navoximod with cisplatin could mitigate chemo-immune resistance through blockading IDO1+ CAFs-secreted kynurenine (Kyn)-aryl hydrocarbon receptor (AhR)-IL-6 via suppressing p-STAT3/NF-κB signals and ceasing AhR-induced loss of pol ζ-caused chromosomal instability (CIN). "

Related Drugs and Biologics

1.	1-methyltryptophan
2.	epacadostat
3.	Vaccines
4.	Peptides (Polypeptides)
5.	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)
6.	atezolizumab
7.	Immune Checkpoint Inhibitors
8.	Hydrogels
9.	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)
10.	Tryptophan (L-Tryptophan)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Immunotherapy